- Establishment Labs press release ( NASDAQ: ESTA ): Q4 GAAP EPS of -$0.55 beats by $0.13 .
- Revenue of $43.81M (+24.1% Y/Y) beats by $0.73M .
- Fourth and final module submitted to U.S. FDA for premarket approval of Motiva Implants ® .
- 2023 guidance of $200 million to $210 million, an increase of 24% to 30% over 2022.
- Cash balance of $66.4 million as of December 31, 2022.
- Mia Femtech™ commercialization on track.
- Motiva Flora ® tissue expander global rollout ongoin.
For further details see:
Establishment Labs GAAP EPS of -$0.55 beats by $0.13, revenue of $43.81M beats by $0.73M